OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
2025.Mar.18
News
New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
2025.Feb.19
News
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
2024.Dec.31
News
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
2024.Dec.23
News
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
2024.Dec.02
News
Key Technologies + Innovative Products + Flexible Business Models
Dr. Heidi Wang: Shaping OBI Pharma into a Leading and Thriving Global Biotech Company
2024.Nov.14
News
OBI Pharma Showcases Biomarker Innovations at Singapore APAC Summit
Precision Medicine Tools Drive Success in New Drug Development
2024.Nov.07
News
OBI Pharma Invited to Speak at World ADC Conference Innovative Linker Technology and GlycOBI® ADC Platform Capture Global Attention
2024.Oct.27
News
OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology
Frequent Speaking Engagements at Prestigious International Conferences
